AKIGAI continues its rapid advancement this autumn: IND, Phase 2b/3, financing and now the Fast Track Designation granted by the FDA. We stay humbled, motivated and on course. The trial starts in Q1_2027 at eight US sites.
Dear patients, the trial sites will be announced shortly.